Brokerages Set Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Price Target at $26.50

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Free Report) has been given a consensus rating of “Buy” by the six research firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $26.50.

Several research firms recently weighed in on ALPN. Royal Bank of Canada upped their price target on shares of Alpine Immune Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Berenberg Bank began coverage on shares of Alpine Immune Sciences in a research report on Tuesday, October 17th. They set a “buy” rating and a $18.00 price target for the company. HC Wainwright upped their price target on shares of Alpine Immune Sciences from $17.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Wedbush increased their price objective on shares of Alpine Immune Sciences from $26.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, January 26th. Finally, Morgan Stanley increased their price objective on shares of Alpine Immune Sciences from $17.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, November 3rd.

Read Our Latest Stock Analysis on ALPN

Alpine Immune Sciences Stock Performance

Shares of Alpine Immune Sciences stock opened at $29.04 on Tuesday. The firm has a 50-day simple moving average of $20.73 and a two-hundred day simple moving average of $15.30. The company has a market cap of $1.69 billion, a P/E ratio of -24.20 and a beta of 1.07. Alpine Immune Sciences has a fifty-two week low of $6.39 and a fifty-two week high of $29.66.

Alpine Immune Sciences (NASDAQ:ALPNGet Free Report) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.11. Alpine Immune Sciences had a negative net margin of 185.10% and a negative return on equity of 33.53%. The business had revenue of $10.04 million during the quarter, compared to the consensus estimate of $8.73 million. Equities research analysts forecast that Alpine Immune Sciences will post -1.14 EPS for the current year.

Insider Activity

In other news, Director Peter A. Thompson sold 181,498 shares of the stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $19.96, for a total value of $3,622,700.08. Following the completion of the sale, the director now owns 406,609 shares of the company’s stock, valued at approximately $8,115,915.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Peter A. Thompson sold 181,498 shares of the stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $19.96, for a total value of $3,622,700.08. Following the completion of the sale, the director now owns 406,609 shares of the company’s stock, valued at approximately $8,115,915.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James Paul Rickey sold 1,800 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $19.00, for a total transaction of $34,200.00. The disclosure for this sale can be found here. Insiders sold a total of 315,182 shares of company stock valued at $6,162,851 in the last 90 days. Company insiders own 42.30% of the company’s stock.

Hedge Funds Weigh In On Alpine Immune Sciences

A number of hedge funds have recently made changes to their positions in the stock. Decheng Capital Management III Cayman LLC purchased a new position in shares of Alpine Immune Sciences during the 3rd quarter worth approximately $76,810,000. BlackRock Inc. boosted its position in shares of Alpine Immune Sciences by 46.9% during the 2nd quarter. BlackRock Inc. now owns 2,281,692 shares of the biotechnology company’s stock worth $23,456,000 after purchasing an additional 728,772 shares during the period. Vanguard Group Inc. boosted its position in shares of Alpine Immune Sciences by 5.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock worth $16,887,000 after purchasing an additional 70,912 shares during the period. Franklin Resources Inc. purchased a new position in shares of Alpine Immune Sciences during the 4th quarter worth approximately $23,260,000. Finally, Geode Capital Management LLC boosted its position in shares of Alpine Immune Sciences by 11.1% during the 2nd quarter. Geode Capital Management LLC now owns 617,974 shares of the biotechnology company’s stock worth $6,353,000 after purchasing an additional 61,767 shares during the period. Hedge funds and other institutional investors own 75.17% of the company’s stock.

About Alpine Immune Sciences

(Get Free Report

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Featured Stories

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.